S-ClassAbout S-Class
M
MEDAI Stock Diagnostic Report
Medifast surges on Q2 earnings beat as turnaround gains traction
[GROQ] MediFast's second-quarter results exceeded expectations, leading to a sharp increase in its stock price.
View Source Article ↗AI CATALYST SCORE90 / 100Score computed by Sentinel V12
REFERENCE PRICE$12.81Reference entry price at analysis time
01
MARKET SNAPSHOT
Key Indicators at a Glance
Major Support9.39
Near-Term Resistance11.16
02
FUNDAMENTALS
Financial & Fundamental Analysis
The GAAP EPS recorded at -$0.28, exceeding market expectations by $0.37, while revenue also achieved $76.4M, surpassing expectations by $3.7M, demonstrating turnaround visibility.
03
TECHNICAL VIEW
Technical Position & Response Criteria
The current stock price has surpassed the previous resistance level of $11.16, indicating a transition into a new upward phase.
Support9.39
Resistance11.16
04
CATALYST & STRATEGY
Catalyst Analysis & Forward Strategy
The announcement of Q2 earnings, which confirmed an earnings surprise and the success of the turnaround strategy, is the direct driver of the 32% surge in the stock price.
05
PROOF OF WORK
Analysis Point vs. Subsequent Price Action
INITIAL · At Analysis (2026-08-04)
FINAL · Current/Verified
Renders the actual stored OHLC data directly in your browser.